Background Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death (SCD), and ...
(Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for ...
On Wednesday, FibroBiologics, Inc. (NASDAQ: FBLG) submitted a new patent application with the U.S. Patent and Trademark Office (USPTO). The patent application covers a proprietary fibroblast-derived ...
Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Advancing Fibroblast Therapy on Multiple Fronts In the past month, ...
Fibrosis is the body's way of patching up damage—a bit like fixing a pothole. When skin is cut or a muscle is injured, ...
Researchers develop a 3D cell culture system to test how inhibiting fibroblast activities can help treat lung cancer. To simulate the tumor microenvironment and mimic real tissues, the team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results